Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Omeprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRS3 | P32247 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Omeprazole SCHEMBL13645390 | 1.00 | BRS3 (0.30) | BRS3 | |
| Omeprazole SCHEMBL13645427 | 1.00 | BRS3 (0.30) | BRS3 | |
| Omeprazole SCHEMBL13645385 | 0.98 | BRS3 (0.33) | BRS3 | |
| Omeprazole SCHEMBL13645305 | 0.97 | BRS3 (0.33) | BRS3 | |
| Omeprazole SCHEMBL13729475 | 0.97 | BRS3 (0.33) | BRS3 | |
| Omeprazole SCHEMBL13645367 | 0.94 | BRS3 (0.36) | BRS3 | |
| Omeprazole SCHEMBL13411612 | 0.93 | BRS3 (0.38) | BRS3 | |
| Omeprazole SCHEMBL13645431 | 0.92 | — | — | |
| Omeprazole SCHEMBL13645270 | 0.91 | BRS3 (0.40) | BRS3 | |
| Omeprazole SCHEMBL13645434 | 0.90 | BRS3 (0.33) | BRS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598273-B2 | Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties | AUSPEX PHARMACEUTICALS, INC (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090215831-A1 | INHIBITORS OF THE GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090209592-A1 | INHIBITORS OF THE GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20070082929-A1 | Inhibitors of the gastric H+, K+-atpase with enhanced therapeutic properties | AUSPEX PHARMACEUTICALS, INC. | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209592-A1 | INHIBITORS OF THE GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES | ATP4A, ATP6V1G1, ATP6V1E1 | BRS3 2346/4885 |
| US-20070082929-A1 | Inhibitors of the gastric H+, K+-atpase with enhanced therapeutic properties | ATP4A, ATP6V1G1, ATP6V1E1 | BRS3 2346/4885 |
| US-20090215831-A1 | INHIBITORS OF THE GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES | ATP4A, ATP6V1G1, ATP6V1E1 | BRS3 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.